NASH market as it stands now
Affecting more than 60 million people worldwide, and with no approved therapies, nonalcoholic steatohepatitis (NASH) presents a wealth of opportunities for drug developers. During the past few years, increased awareness has led to significant clinical activity in the disease area, with a plethora of companies vying for the first-to-market status for their products. Currently, there are eleven novel drugs in late-stage development for NASH across the 7MM (US, France, Germany, Italy, UK, Spain and Japan), with anticipated launch dates in 2021-2025.
GlobalData Insights & Analysis related to this topic
Research was conducted to examine current trends and to understand the future potential of the pipeline agents in the NASH market. Based on insights gathered from key opinion leaders (KOLs), it is anticipated that the market will grow rapidly by more than forty-fold, from $618m in 2016 to around $25.3bn at the end of 2026. The initial uptake of the drugs will be slow, due to their high cost and reimbursement issues. Towards the end of the forecast period, it is expected that these drugs will displace the currently available off-label treatments, the driver for growth being the launch of diagnostic biomarkers which will provide evidence of treatment outcomes and enhance reimbursement prospects.
GlobalData’s Managing Analyst within Immunology, Lakshmi Dharmarajan explains that this analysis has “highlighted the significant opportunity in the NASH market for the development of drugs with different mechanisms-of-action in order to effectively treat the heterogeneous patient population.” In addition, the analysis includes insights from KOLs about which of the pipeline drugs (in Phase IIb and Phase III) appear to be most promising. The research further underlines the types of R&D strategies that should be employed by pharmaceutical companies in order to succeed in the competitive NASH market, all of which will be explored in the ‘Understanding the NASH Market Landscape’ webinar.
– Comments provided by Lakshmi Dharmarajan, Managing Analyst at GlobalData.
– Information based on GlobalData’s webinar: Understanding the NASH Market Landscape
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
GlobalData Healthcare is a market-leading provider of valuable and in-depth market research for the Pharmaceutical, Biotechnology and Medical Device industries.
For more information
Please get in contact if you have any questions about this or other GlobalData products. Analysts are available to comment. Contact the GlobalData press office +44 (0)161 359 5822 or email firstname.lastname@example.org.